Introduction
Human adenoviruses of serotype 2 and 5 are acknowledged as promising genedelivery vehicles. However, in vivo utility of these adenovirus vectors (AdVs) is hampered by their promiscuous tropism. The broad array of cell types infected by adenovirus leads to AdV transduction of undesired tissues and reduces the fraction of the administered dose available for transduction of specific target cells. The liver is the major target of AdV transduction in mice following systemic administration and accounts for more than 99% of total transduction (1) (2) (3) (4) . The liver also is targeted in non-human primates, although in these animals a significant fraction of the administered AdV dose transduces the spleen (5) . An additional complication of AdV administration in humans is the interaction of the vector with erythrocytes (6, 7) . In contrast to murine erythrocytes, human erythrocytes are efficiently bound by AdVs, which prevents specific transduction of target cells. In blood samples obtained from a patient enrolled in a clinical gene therapy trial, greater than 98% of the virus was associated with erythrocytes (7) . Thus, the native tropism of adenovirus diminishes the in vivo efficacy of AdVmediated gene delivery. To circumvent this problem and enhance the specificity of AdV transduction, a new generation of AdVs is required. Such vectors should eliminate native adenovirus tropism and incorporate unique target-binding moieties.
The tropism of adenovirus types 2 and 5 is determined by at least three distinct receptor-binding sites on the viral capsid. These sites mediate attachment to the coxsackievirus and adenovirus receptor (CAR), α v integrins, and heparin sulphate glycosaminoglycans (HSG), respectively (8) (9) (10) (11) (12) (13) . Recently, also blood coagulation factors FVII, FIX, FX and protein C and complement component C4-binding protein (C4BP) were shown to play a role in adenovirus' tropism by bridging adenovirus to cell-surface receptors (14, 15) . Ablation of the direct receptor interactions can be accomplished by modification or elimination of the receptorbinding sequences, which induces a change in the in vivo biodistribution of AdVs in mice, rats, and non-human primates (2, 4, 5, (16) (17) (18) (19) . Remarkably, whereas CAR forms the primary receptor for AdVs in vitro, ablation of the CAR-binding site alone does not substantially affect the biodistribution of AdVs in vivo (2, 3) . Instead, alteration of at least two binding sites is required to influence AdV biodistribution. AdVs lacking binding sites for both CAR and α v integrins exhibit significantly decreased transduction of the heart, kidney, liver, and lung (2, 4) .
Ablation of the HSG-binding site in combination with alteration of the binding sites for either CAR or α v integrins also reduces transduction of many organs (4, 17) . Not unexpectedly, the most substantial reduction in tissue transduction is obtained when all three binding sites are altered (4, 19) . Ablation of native tropism (de-targeting) has to be combined with the introduction of new tropism to come to the ultimate AdV with beneficial properties for in vivo application. Generally, two strategies have been used to provide AdVs with new tropism: a one-component strategy, which is based on genetic modification of fiber or another capsid component, and a two-component strategy, which relies on the use of bi-specific adapter molecules (20) . There are advantages and disadvantages of each. The one-component strategy is better defined and more feasible for generation of clinically applicable targeted vectors. It also is better suited for design of targeted oncolytic adenoviruses, which rely on efficient in vivo production of targeted viral progeny to produce anti-tumor effects. Since the fiber molecule principally defines adenovirus tropism, most targeting approaches exploit this capsid protein as a platform for display of novel binding entities. However, insertion of large and complex folded ligands into the fiber can alter its structure and preclude encapsidation onto the virus particle. Several groups including our own have developed chimeric attachment molecules in which the fiber knob is replaced with an exogenous trimerization domain (21) (22) (23) . This strategy allows the introduction of complex receptor-binding moieties and simultaneously causes partial ablation of native AdV tropism by removal of the CAR-binding site. Until recently, application of such targeted AdVs was severely limited by their impaired propagation efficiency, which necessitated wildtype fiber complementation for their production.
We recently reported the generation of a new genetically targeted AdV, AdG.L.Tail-T(ii)-MH, which contains the chimeric attachment molecule Tail-T(ii)-MH replacing the fiber (24) . Tail-T(ii)-MH consists of the tail domain of adenovirus fiber, the T(ii) oligomerization domain of reovirus attachment protein σ1, and Cterminal Myc and polyhistidine tags. Therefore, AdG.L.Tail-T(ii)-MH lacks binding sites for CAR and HSG, for the 'bridging' factors FIX and C4BP, and most likely for FVII, FX and protein C as well (14, 15) . Instead, this AdV is targeted to an artificial His-tag binding receptor which allows efficient propagation on packaging cells expressing this receptor without fiber complementation (24) . To further reduce native adenovirus tropism for systemic in vivo gene delivery, we generated a derivative of AdG.L.Tail-T(ii)-MH, AdG.L.p*Tail-T(ii)-MH, which lacks the integrin-binding site as well. In this study, we evaluated both Tail-T(ii)-MH-containing AdVs for targeting specificity, liver cell transduction, and biodistribution following intravenous inoculation of mice. In comparison to control AdV, AdG.L.p*Tail-T(ii)-MH displays substantially enhanced bioavailability and diminished tissue transduction. This new AdV thus offers a promising platform for the design of highly targeted AdVs for numerous gene-delivery applications.
Materials and Methods

Cell lines
The Ad5 E1-transformed human embryonic kidney cell line 293 and the human hepatoma cell line HepG2 were purchased from the American Type Culture Collection. The cell line 293.HissFv.rec is a derivative of the cell line 293 that stably expresses an artificial His-tag binding receptor (25) . Cell lines were maintained in F12-supplemented Dulbecco modified Eagle medium (DMEM F-12) supplemented to contain 10% fetal calf serum and antibiotics (Gibco BRL, Life Technologies B.V., Breda, The Netherlands). Medium used for 293.HissFv.rec was supplemented to contain 300 µg/ml of G418.
Adenoviral vectors
The genetically targeted AdV, AdG.L.Tail-T(ii)-MH, and the control vector, AdG.L, were described previously (24) . Both AdVs contain GFP and luciferase reporter genes in the E1 locus. AdG.L expresses wild-type fiber and penton base genes conferring native adenovirus tropism, whereas AdG.L. (24) .
Immunoelectron microscopy
Immunoelectron microscopy was performed as described (27) . CsCl-purified virions were spotted onto carbon-coated copper grids and incubated with antiknob monoclonal antibody (MAb) 1D6.14 (28), anti-Myc MAb 9E10, or anti-(His) 5 Penta-His antibody (Qiagen, Hilden, Germany). Grids were subsequently incubated with rabbit anti-mouse serum (Dako Cytomation A/S, Copenhagen, Denmark), followed by gold-labeled protein-A (Amersham Biosciences Europe GmbH, Freiburg, Germany). After fixation (1.5% glutaraldehyde) and negative staining (1% uranyl acetate), virions were visualized using a Philips EM 410-LS transmission electron microscope.
Immunoblot analysis
CsCl-purified virions of each AdV (5 x 10 9 vp) were incubated at 95°C for 5 min in denaturating sample buffer (62. 
and AdG.L.p*Tail-T(ii)-MH were either untreated or pre-incubated with 330 ng 1D6.14 MAb or 300 ng Penta-His antibody at room temperature for 1.5 h. After 2 h adsorption to cells, the inoculum was removed, fresh medium was added, and cells were incubated for 48 h. GFP expression was assessed using fluorescence microscopy, or cells were lysed in 50 µl reporter lysis buffer (Promega, Madison, WI, USA), and luciferase activity was measured using the Chemiluminescent Luciferase Assay (Promega) and a Berthold luminometer (Berthold, Bad Wildbad, Germany). Infection of liver tissue was assessed using liver slices prepared from freshly isolated mouse livers. Livers were resected from C57BL/6 mice, placed in ice-cold Krebs buffer (25 mM D-glucose, 25 mM NaHCO 3 and 10 mM HEPES), and immediately processed by drilling cores of 8 mm in diameter. Cores were sliced at a thickness of 200-250 µm using a Krumdieck tissue slicer (Alabama R&D, Muntfort, AL, USA) in ice-cold Krebs buffer. Liver slices were transferred to 12-well plates and pre-incubated for 1 h in Williams' medium E (WME) supplemented to contain 25 mM D-glucose and antibiotics (Gibco BRL) at 37ºC in a 95% O 2 and 5% CO 2 atmosphere. Slices then were incubated with 10 8 vp/slice (~100 vp/cell) in oxygenated WME medium at 37ºC under continuous rocking in a 95% O 2 , 5 % CO 2 climate chamber. After 72 h incubation, slices were lysed in 50 µl CCLR lysis buffer (25 mM Tris-phosphate, 20 mM CDTA, 200 mM DTT, 10% glycerol, 1% Triton X-100) at room temperature for 15 min, followed by three freeze-thaw cycles. Lysates were cleared by centrifugation, and luciferase activity was assessed using 10 µl of the supernatant. Luciferase activity was normalized on the basis of protein concentration as determined by the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA).
Biodistribution of AdVs
Female C57BL/6 mice weighing 20-25 g were obtained from Harlan-CPB (Harlan, Horst, The Netherlands), fed a standard laboratory diet, provided water ad libitum, and allowed to acclimatize for at least one week prior to the initiation of experiments. Mice were randomly divided into three groups of at least 5 animals each and inoculated with 10 inoculated with a mixture of 2 µl whole blood and 50 µl DMEM-F12. After 48 h incubation, 293HissFv.rec cells were lysed in reporter lysis buffer (Promega), and luciferase activity was determined. AdV concentration was calculated using a standard curve, which was generated with known concentrations of the corresponding AdV. Transduction of mouse tissues by AdVs was determined 48 h following intravenous administration. Mice were euthanized, and liver, spleen, kidneys, lungs and heart were resected. Tissues were snap-frozen in liquid nitrogen and homogenized using a mortar and pestle. A 25 mg aliquot of tissue was lysed in 100 µl CCLR lysis buffer by incubation at room temperature for 10 min, followed by two freeze-thaw cycles. Lysates were cleared by centrifugation, and transduction of each tissue was determined by luciferase activity in 20 µl lysate. Luciferase activity was normalized for protein concentration as determined by the Bio-Rad protein assay. Differences in tissue transduction by the three AdVs were evaluated with a one-tailed Mann-Whitney test using GraphPad Instat 3.0 (GraphPad Software, Inc., San Diego, CA). The experimental protocols adhered to the rules outlined in the Dutch Animal Experimentation Act and the "Guidelines on the Protection of Experimental Animals" by the council of the European Community and were approved by the Committee on Animal Research of the VU University Medical Center.
Interaction of AdV with human erythrocytes
Blood of mice, rats, or humans was collected in EDTA-tubes and mixed with 1 vol equivalent of Alsever solution (23 mM Tri-sodium citrate, 114 mM glucose, 55 mM NaCl, and 3 mM citric acid [pH 6.1]). Cells were centrifuged at 1,200 g for 10 min and washed three times by repeated resuspension in 2 vol equivalents of Alsever solution and centrifugation at 1,200 g for 10 min. The final pellet was resuspended in Alsever solution to generate a 30% packed-cell suspension.
Hemagglutination was assayed using a 1% erythrocyte suspension, which was generated by dilution of the 30% packed-cell suspension in HA-buffer (PBS, 0.005% BSA). A volume of 50 µl 1% erythrocyte suspension was prelayed in wells of a concave-bottom-shaped 96-well plate and gently mixed with 50 µl of a dilution series of each AdV (stock concentration, 10 12 vp/ml). After 2 h gravitational sedimentation, plates were photographed and analyzed for hemagglutination.
Binding of AdV virions to erythrocytes was quantified by determining the number of adherent AdV genomes using quantitative PCR (qPCR). A 30% packed-cell suspension of human erythrocytes was diluted in PBS to a physiological concentration of 8. 
Results
Vector generation and characterization
To achieve complete ablation of native adenovirus tropism, we generated a new AdV, AdG.L.p* Tail 
Transduction profile of targeted AdVs
To assess the effect of ablation of native adenovirus tropism and introduction of a binding sequence that engages an artificial His-tag binding receptor, we 
In vitro and ex vivo liver de-targeting
Since the majority of intravenously administered adenovirus is captured in the liver either via transduction of hepatocytes or uptake in Kupffer cells, the primary goal of adenovirus de-targeting for systemic administration is to limit liver sequestration. To determine whether the targeted AdVs display altered hepatic tropism, we first analyzed transduction efficiency using the human hepatoma cell line HepG2. HepG2 cells were inoculated with 1,000 vp/cell, and transduction efficiency was determined 48 h after incubation by quantifying luciferase activity (figure 8 Transduction efficiency by the test vectors was quantified by luciferase activity in liver-slice lysates (figure 8.3B). As expected, AdG.L showed efficient liver cell transduction. In contrast, ablation of native binding sites in AdG.L.Tail-T(ii)-MH and AdG.L.p*Tail-T(ii)-MH was associated with a 10,000-fold reduction in liver transduction. In fact, the level of luciferase expression caused by the two targeted AdVs did not differ significantly from that of control slices transduced by AdDsRed, which does not express luciferase. These findings suggest that the targeted AdVs display markedly diminished tropism for the mouse liver.
Biodistribution of targeted AdVs in C57BL/6 mice
To directly evaluate the effect of ablation of native adenovirus tropism in vivo, we inoculated C57BL/6 mice with 10 10 AdV particles intravenously. During the first 2 h after inoculation, blood samples were drawn from the tail vein, and AdV titers were determined using 293.HissFv.rec cells (figure 8.4A). All three AdVs exhibited a biphasic clearance pattern with a rapid decrease during the first 30 min, followed by a slower decrease over the remaining 90 min. AdG.L exhibited the most rapid clearance with less than 1% of the administered dose detectable at 10 min and approximately 0.1% at 20 min. Although the clearance profile of AdG.L.Tail-T(ii)-MH suggests a somewhat improved bioavailability in the first 30 min after administration, clearance of this AdV did not differ significantly from that of AdG.L in the interval thereafter. In contrast, the half-life of AdG.L.p*Tail-T(ii)-MH immediately following inoculation was prolonged, with approximately 10% of the administered dose detected in the circulation at 10 min and 1% at 30 min. The virus then exhibited a rate of clearance identical to that of the other two vectors but at an approximately 10-fold higher concentration. Thus, AdG.L.p*Tail-T(ii)-MH displays enhanced bioavailability in the blood in the first 2 h after inoculation in comparison to the other AdVs.
To determine transduction efficiency of mouse tissues following intravenous administration of AdVs, mice were sacrificed 2 days post-inoculation, organs were resected and processed for luciferase assay (figure 8.4B). As expected, AdG.L preferentially transduced the liver, consistent with several previous reports (2, 4, 5, (16) (17) (18) (19) . Removal of the native adenovirus binding sites in the targeted AdVs significantly reduced liver transduction. In comparison to the control vector, AdG.L.Tail-T(ii)-MH exhibited a 70% (P < 0.05) reduction in liver transduction and AdG.L.p*Tail-T(ii)-MH exhibited an 83% (P < 0.01) reduction. Transduction of other tissues by AdG.L.Tail-T(ii)-MH also was reduced, reaching statistical significance for the heart (75%; P < 0.05) and lung (50%; P < 0.05). In contrast, transduction by AdG.L.p*Tail-T(ii)-MH was significantly diminished for all tissues tested. Transduction of the heart and spleen by AdG.L.p*Tail-T(ii)-MH was reduced 75% (P < 0.05) and 66% (P < 0.01), respectively, and transduction of the kidney and lung were reduced to background levels (P < 0.01). The results are expressed as mean luciferase activity in LU/mg protein for at least 5 independent experiments. Error bars indicate standard deviations. *, P<0.05; **, P < 0.01.
AdV interactions with red blood cells
AdVs with native tropism bind and agglutinate erythrocytes of human and rat but not murine origin (6, 18) . Interactions with human erythrocytes constitute a major roadblock for therapeutic application of AdVs. Therefore, we tested the targeted AdVs for erythrocyte binding and agglutination (figure 8.5A and Table 8 .2). Native AdV AdG.L produced hemagglutination of human and rat erythrocytes but not mouse erythrocytes, as anticipated. However, neither AdG.L.Tail-T(ii)-MH nor AdG.L.p*Tail-T(ii)-MH produced hemagglutination of any of the erythrocytes tested.
To corroborate these findings, we determined the fraction of each AdV bound to human erythrocytes. AdVs were incubated with human erythrocytes, and AdV genomes in cell (bound) and supernatant (unbound) fractions were quantified using qPCR ( figure 8 .5B). AdV with native tropism bound human erythrocytes efficiently, leaving less than 5% of the inoculum in the supernatant. In sharp contrast, the affinity of AdG.L.Tail-T(ii)-MH and AdG.L.p*Tail-T(ii)-MH for human erythrocytes was markedly reduced, with greater than 90% of the inoculum remaining in the supernatant. Thus, ablation of native adenovirus tropism substantially compromises the capacity of targeted AdVs to interact with human erythrocytes. 
Species of origin RBC Virus vector
Hemagglutination scored according to the scale described by Cichon et al. (6) : -, no hemagglutination; +, short-range hemagglutination; ++, medium-range hemagglutination; +++, long-range hemagglutination 
Discussion
Targeting AdVs to specific cells by complete abrogation of native adenovirus tropism and introduction of a unique binding moiety should improve the in vivo applicability and efficacy of these vectors. We previously generated a genetically targeted AdV, AdG.L.Tail-T(ii)-MH, by replacing the adenovirus fiber molecule with a prototype chimeric attachment protein, which lacks CAR-and HSG-binding sites and confers His-tag-dependent tropism (24) . In addition, deletion of the fiber knob removed putative binding sites for coagulation factors FVII, FIX, FX, protein C and complement component C4BP, which are shown to link adenovirus to alternate cell-surface receptors (14, 15) . This vector design has the potential to incorporate large and complex proteins as ligands and allows vector propagation without the need for complementing fiber.
In this study, we substantially improved the AdG.L.Tail-T(ii)-MH platform to facilitate systemic in vivo administration by ablating the final known adenovirus attachment site, the integrin-binding motif, from the viral capsid. Importantly, this modification did not affect efficient propagation of the vector using cells that express an artificial His-tag binding receptor. In fact, the new genetically targeted vector, AdG.L.p*Tail-T(ii)-MH, replicates in His-tag receptor-expressing cells efficiently and achieves viral particle yields that approximate those of an AdV with native tropism. We conclude that binding of the chimeric attachment protein to the artificial His-tag binding receptor is sufficient for AdV internalization and delivery of the viral genome to the nucleus, thus allowing efficient virus replication and transgene expression. This suggests that retention of the presumably physiologically inert His-tag in derivative targeted AdVs incorporating selective binding ligands of choice will allow their efficient production using Histag receptor-expressing cells. Therefore, production of a variety of genetically targeted AdVs with different binding specificities should be possible using a single packaging cell line. Many studies have shown that intravenous administration of native AdV expressing luciferase usually results in very high luciferase activity per mg protein in the liver with approximately 100-fold lower levels in other tissues (2-4, 19, 30) . However, we found approximately 70% of AdG.L activity in the liver and 10-15% in lungs and spleen. This was more in line with a previous observation by Seki et al (31) who found a similar transduction efficiency of the liver and an even more efficient transduction of the spleen. We can only speculate as to why the biodistribution profile of AdV with native tropism differed considerably between individual studies using similar methods. Perhaps this could be partially explained by differences in the injected AdV dose. (2, 4) . Since the kidney and lung sequester only a minor fraction of systemically administered AdV, very effective de-targeting of those tissues might not increase target-cell transduction or substantially prolong circulation half-life. In absolute terms, the modest reduction in liver transduction is likely to have a larger impact on bioavailability than the complete de-targeting of kidney and lung. However, effective de-targeting of kidney and lung establishes a framework for the development of highly selective target-cell transduction of those tissues by isolated organ perfusion. This approach might be an attractive option for AdV oncolytic treatment of primary malignancies originating from kidney or lung or metastasic lesions involving those organs. Such approaches could be considered as alternatives for systemic gene delivery if liver and spleen transduction cannot be entirely abolished. Reduced uptake of AdG.Lp*Tail-T(ii)-MH in tissues was associated with increased vector levels in the circulation. We think it is important that the assay used to quantify virus in the circulation, measured particles capable of transducing target cells. Therefore, AdVs detected in the circulation represented bioavailable AdVs. 
. Rather, our findings localize the erythrocyte-binding site to the fiber shaft or knob domain, which is in agreement with a previous report that mapped hemagglutination capacity to the CAR-binding site (18) . Thus, targeted AdVs encoding Tail-T(ii)-MH attachment molecules evade potential sequestration by human erythrocytes, suggesting that AdVs based on this platform would have prolonged bioavailability in the circulation of humans. In this study, we developed a prototype targeted AdV, AdG.L.p*Tail-T(ii)-MH, which incorporates many desirable features for systemic gene delivery. Although caution should be taken in extrapolating observations using mouse models to humans, the highly specific transduction profile, improved bioavailability, and absence of erythrocyte binding of AdG.L.p*Tail-T(ii)-MH bring systemic application of AdV-based gene delivery in closer proximity and warrant further investigation.
